With the finalization of ICH GCP (R2), sponsors and CROs are actively looking into implementation of a Risk Based Monitoring (RBM) approach to their clinical trials to achieve the objectives related to enhanced data quality, better monitoring of patient safety, and creating efficiencies in overaOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.